Stanley-Laman Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Stanley-Laman Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$247K	Buy	553 +68	+14%	+$31.7K	0.03%	263
2025 Q4	$220K	Buy	+485	New	+$209K	0.03%	267
2025 Q3	–	Sell	-668	Closed	-$297K	–	322
2025 Q2	$297K	Sell	668 -334	-33%	-$154K	0.04%	236
2025 Q1	$486K	Buy	+1,002	New	+$467K	0.07%	198
2024 Q4	–	Sell	-436	Closed	-$203K	–	298
2024 Q3	$203K	Buy	+436	New	+$209K	0.03%	283
2022 Q2	–	Sell	-1,323	Closed	-$345K	–	310
2022 Q1	$345K	Buy	+1,323	New	+$314K	0.05%	215
2021 Q1	–	Sell	-2,168	Closed	-$512K	–	267
2020 Q4	$512K	Buy	2,168 +964	+80%	+$221K	0.09%	209
2020 Q3	$328K	Buy	+1,204	New	+$332K	0.07%	201
2019 Q1	–	Sell	-1,498	Closed	-$248K	–	272
2018 Q4	$248K	Buy	+1,498	New	+$260K	0.07%	231

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Stanley-Laman Group's VRTX Position: Q1 2026 in Review

Stanley-Laman Group increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2026, buying an estimated $31.7K and bringing the position to 553 shares worth $247K. The position accounts for 0.03% of the portfolio, ranked #263.

Stanley-Laman Group first reported a position in VRTX in Q4 2018 and has held it in 9 quarters since. The position peaked at $512K in Q4 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Stanley-Laman Group held 553 shares of Vertex Pharmaceuticals worth $247K as of Q1 2026.
Stanley-Laman Group bought 68 Vertex Pharmaceuticals shares in Q1 2026, an estimated $31.7K.
Vertex Pharmaceuticals made up 0.03% of Stanley-Laman Group's portfolio in Q1 2026, its #263 holding.
Stanley-Laman Group first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 9 quarters since.
Stanley-Laman Group's Vertex Pharmaceuticals position peaked at $512K in Q4 2020.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Stanley-Laman Group's 13F filing for Q1 2026, filed 16 Apr 2026.